Cancers, Vol. 15, Pages 4354: Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis

In conclusion, the overall prevalence of hematological AEs by TKI type was: dasatinib > bosutinib > imatinib > nilotinib. Study limitations include inability to normalize for dosage and treatment duration.

Source: Cancers - August 31, 2023 Category: Cancer & Oncology Authors: Olivia Kronick Xinyu Chen Nidhi Mehra Armon Varmeziar Rachel Fisher David Kartchner Vamsi Kota Cassie S. Mitchell Tags: Systematic Review Source Type: research